Advanced Bitcoin Technologies AG Q2 FY2024 Earnings Call

· Earnings call transcript and AI-powered summary

  • Organic Sales Growth: Excluding COVID testing, organic sales rose 9.3%, driven by strong performance across all core businesses.
  • Earnings Per Share (EPS): Adjusted EPS was $1.14, a 16% increase sequentially from Q1 2024 and surpassing analyst estimates.
  • Updated Guidance:
    • Full year 2024 organic sales growth (excluding COVID testing) now projected at 9.5%–10%.
    • Full year adjusted EPS forecast raised to $4.61–$4.71 (up from prior guidance).
    • Q3 2024 adjusted EPS expected between $1.18–$1.22.

Business Segment Highlights (Compared to Q2 2023)

  • Medical Devices: Sales rose 12%, led by:
    • Diabetes Care: Freestyle Libre sales up 20% to $1.6B; two new FDA-approved OTC CGM systems (Lingo and Libre Rio) announced.
    • Electrophysiology: Sales grew 17%, with 20% growth in ablation catheters and increased market activity.
    • Structural Heart: Grew over 15% due to launches like TriClip and strength in Amulet (+45%).

Continue Reading

Unlock the full AI-powered summary with key highlights, financial performance, and analyst Q&A.

Upgrade to Professional
Operator: Good morning and thank you for standing by. Welcome to Abbott’s second quarter 2024 earnings conference call. All participants will be able to listen only until the question and answer portion of this call. During the question and answer session, you will be able to ask your question by pressing the star-one-one keys on your touchtone phone. This call is being recorded by Abbott. With the exception of any participants’ questions asked during the question and answer session, the entire call including the question and answer session is material copyrighted by Abbott. It cannot be recorded or rebroadcast with Abbott’s express written permission. I would now like to introduce Mr. Mike Comilla, Vice President, Investor Relations. Mike Comilla: Good morning and thank you for joining us. With me today are Robert Ford, Chairman and Chief Executive Officer, and Phil Boudreau, Executive Vice President, Finance and Chief Financial Officer. Robert and Phil will provide opening remarks. Following their comments, we’ll take your questions. Before we get started, some statements made today may be forward-looking for purposes of the Private Securities Litigation Reform Act of 1995, including the expected financial results for 2024. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological, an

Continue Reading

Unlock the full earnings call transcript with speaker labels and formatted dialogue.

Upgrade to Professional